Skip to main content

Vuity FDA Approval History

FDA Approved: Yes (First approved October 28, 2021)
Brand name: Vuity
Generic name: pilocarpine hydrochloride
Dosage form: Ophthalmic Solution
Company: AbbVie Inc.
Treatment for: Presbyopia

Last updated by Judith Stewart, BPharm on Nov 10, 2021.

Vuity (pilocarpine hydrochloride) is an optimized ophthalmic solution formulation of the approved cholinergic muscarinic receptor agonist pilocarpine indicated for the treatment of presbyopia (age-related blurry near vision).

Development timeline for Vuity

DateArticle
Oct 29, 2021Approval FDA Approves Vuity (pilocarpine HCI ophthalmic solution) to Treat Presbyopia (Age-Related Blurry Near Vision)
Oct 26, 2021Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
Jul 25, 2021New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
Feb 25, 2021Allergan Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.